José Jesús Broseta Monzó

🩺 Nephrologist @HospitalClinic. 🧑🏻‍🏫 Associate professor @CampusClinicUB👨🏻‍🎓MD, PhD. Nephro🫀 and 🏠 dialysis. 🎼Classical musician. 🥘Valencian.

[ERA - European Renal Association @ERAkidney]

🧵 Symposium: Non-pharmacological approaches to cardiovascular complications in CKD #ERA26

🎙️Chaired by Jonathan Gabriel Fox & Milica Bozic

🫀Cardiovascular disease (#CVD) remains the leading cause of morbidity and mortality across the #CKD spectrum.
🟢Beyond💊: exercise, diet and the microbiome as CV therapies in CKD

Today’s speakers will discuss:

👟Exercise training and cardiovascular disease in severe CKD — Naomi Clyne
🧂 Sodium and potassium: the yin and yang of hypertensive vascular disease — Johannes Stegbauer
🦠 The gut microbiome and cardiovascular burden in CKD — Laetitia Koppe

Follow this thread for key insights 👇

[ERA - European Renal Association @ERAkidney]

🧵 Free Communications 18: Bones, Hearts & Metabolism: Dialysis Complications Unpacked #ERA26

Chaired by Jovana Kusic Milicevic and Pieter Evenepoel.

Today’s session explores key complications in hemodialysis:
🩸 Bleeding risk and anticoagulation
🦴 Osteoporosis and fractures
❤️ Cardiovascular risk prediction
🏃 Exercise-based cardioprotection

Follow this thread for the key findings 👇

[ERA - European Renal Association @ERAkidney]

#ERA2026

💡Interesting work comparing HV-HDF and HDx using different β2-microglobulin clearance metrics.

✅As expected, HV-HDF achieved higher β2M clearance.

✅The novel aspect was the evaluation of eCDCβ2M, an equivalent continuous clearance metric that may better reflect middle-molecule kinetics than traditional reduction ratios or urea-derived measures.

The next challenge: proving that these metrics predict clinical outcomes, not just toxin removal.

#Nephrology #Dialysis #HDF #HDx

[ERA - European Renal Association @ERAkidney]

#ERA2026

39,750 patients. 583,457 HDF sessions.

🏋️ Lean tissue mass → higher substitution volume

🫃 Fat tissue mass → no independent association

💡Perhaps it's time to move beyond body size and consider body composition when evaluating and comparing convective dose delivery in HDF.

#Nephrology #Dialysis #HDF #BodyComposition

[CKJ @CKJsocial]

Deciding between conservative kidney management and dialysis in older people with kidney failure: a narrative review

https://t.co/WetrWngYZJ

[ERA - European Renal Association @ERAkidney]

🧵 Symposium: Multiple health conditions (multimorbidity) in CKD #ERA26

🎙️Moderated by Patrick Mark and Siren Sezer.

#Multimorbidity affects most people living with #CKD and has major implications for prognosis, risk prediction and patient-centred care.

Today’s speakers:
🧓🏻Multimorbidity in older adults with CKD - Giorgi Beridze
📊Dialysis risk prediction in complex patients - Heather Walker
🧠Mental health in CKD - Kenneth Farrington

Follow this thread for the key insights 👇

[ERA - European Renal Association @ERAkidney]

Sodium Glucose Cotransporter 2 Inhibitors in Kidney Transplant Recipients | #ERA26

Non Diabetic Recipients: Barcelona cohort showed sodium glucose cotransporter 2 inhibitor initiation led to significant proteinuria reduction and estimated glomerular filtration rate stabilization in non diabetic kidney transplant recipients. A dedicated double blind placebo controlled randomized controlled trial is now recruiting.

Mechanisms Beyond Glucose:
Reduced intraglomerular pressure and natriuresis via tubuloglomerular feedback
Anti fibrotic effects via transforming growth factor beta mediated suppression and reduced tubular stress
May act as pharmacological reinnervation after kidney transplantation due to ischemia reperfusion injury and loss of sympathetic innervation

Ongoing Trials:
SGL-TX-GFR: 88 non diabetic recipients with estimated glomerular filtration rate greater than 25, testing 10 milligram dapagliflozin versus placebo for 18 months. Outcomes include graft function, safety, urinary tract infections, post transplant diabetes, albuminuria
RENAISSANCE: 900 adult recipients 6 months post transplant. Tests if sodium glucose cotransporter 2 inhibitor reduces death, graft loss, major cardiovascular events, and estimated glomerular filtration rate decline
RENAL LIFECYCLE: Includes kidney transplant recipients with estimated glomerular filtration rate less than or equal to 45. Expectation is reduction in all cause mortality, renal failure, and heart failure hospitalizations with and without type 2 diabetes

Meta-Analysis: 32 studies with 7834 kidney transplant recipients showed sodium glucose cotransporter 2 inhibitors and glucagon like peptide 1 receptor agonists associated with improved survival, cardiovascular, and kidney outcomes with favorable safety profile.

Safety and Use: Current observational, real world, and randomized controlled trial data do not suggest excess risk post transplant. Safety signals need vigilance. While awaiting definitive randomized controlled trial data, pragmatic adoption in select high risk groups is encouraged.

Takeaway: Sodium glucose cotransporter 2 inhibitors have strong biological rationale and emerging data for graft and cardiovascular protection in kidney transplant recipients, including non diabetic patients.

Presentation: Adnan Sharif | Tweet: @eroldemir83

[ERA - European Renal Association @ERAkidney]

simultaneous publication during #ERA26

[José Jesús Broseta Monzó @jbroseta]

🎧 Escúchalo aquí:

🍎 Apple Podcasts:
https://t.co/3tF1gUcmnQ

🟣 iVoox:
https://t.co/SJ5ZNppAxf

🟢 Spotify:
https://t.co/uqT2S7o4NU

@SENefrologia @nefrocat @catcardio

[José Jesús Broseta Monzó @jbroseta]

📻 En el Episodio 3 de #CaReCAST hablamos de la importancia de detectar precozmente la #ERC dentro del síndrome cardiorrenometabólico.

🔎 Albuminuria
🔎 FG
🔎 Biomarcadores
🔎 Prevención CV y renal
🔎 Nuevos tratamientos

Porque detectar antes significa cambiar pronóstico.

[Edgar V. Lerma 🇵🇭 @edgarvlermamd]

Kidney disease (CKD) and heart failure (HFrEF, HFpEF): recent advances and current challenges: conclusions from @goKDIGO Controversies Conference ca. 2026 from @Kidney_Int
#Nephpearls #Cardiorenal

👉 https://t.co/VPlVfQLLxj

[Gunnar Henrik Heine @gunnar_heine]

Obesity in CKD: Core Curriculum 2026
https://t.co/fA8MBqCpVw

[CKJ @CKJsocial]

Chloride at the spotlight—but not alone: toward a multi-ionic diuretic strategy

https://t.co/TIIxvhI7DE

[ERA - European Renal Association @ERAkidney]

1/10 🧵 Recent Clinical Trials in AKI

An @erakidney e-seminar of the ERAKI working group
Speaker: Nicholas Selby 🇬🇧
Moderator: Marlies Ostermann @MarliesOst 🇬🇧
Panelist: Vincenzo Cantaluppi 🇮🇹
Panelist: Joana Gameiro @jogameiro 🇵🇹

👉Acute kidney injury complicates patient’s clinical course,
💊however there is no drug for the treatment so far!

👇👇Exiciting new studies regarding AKI management addressed in this seminar

[Diana Rodríguez Espinosa @dianarodespi]

💥Metaanálisis con datos individuales de >285k pacientes (46 RCTs):

✅↓5 mmHg PAS ➡️ ↓eventos CV mayores tanto en ERC como sin ERC.

✅Beneficio consistente incluso en ERC G4–5 y con PA basal <120/70.

⚠️ Efecto aparentemente atenuado en ERC + DM.

👇🏼
https://t.co/K4rZQyFkhR

[José Jesús Broseta Monzó @jbroseta]

Great discussions today at the @AstraZeneca tutorials during @escardio #HeartFailure26 on multimorbidity and the need for stronger multidisciplinary collaboration in heart failure and CKD care. #CardioRenal

A pleasure to share perspectives with colleagues across specialties.

[Hospital Clínic @hospitalclinic]

🌞 Tant si plou com si fa sol, el #ClínicObert ja està en marxa!

💪🏼 Hi ha mes de 100 activitats per apropar la #salut, la ciència i la innovació a la ciutadania.

T’hi esperem ☺️

[José Jesús Broseta Monzó @jbroseta]

Otro año participando en el #ClinicObert del @hospitalclinic. Promoviendo la salud y dando a conocer, junto a @caravaca_pedro y el equipo de comunicación, nuestro día a día con mucho humor.

[Rosa @30965rrs]

Es un orgullo y una gran responsabilidad ver que nuestras plazas de #Nefrología en el @hospitalclinic de Barcelona han sido elegidas en el primer día de adjudicación #MIR2026 Motivación seguir trabajando por la excelencia asistencia. BIENVENIDOS!!!! 🎊🎉🙌🏼

[Novi Yanti Sari @slumberbell]

30-60% of #HeartFailure patients also have #CKD, & this overlap markedly increases the risk of hospitalization🏥 & death☠️

Despite major advances in each condition, important gaps remain when they coexist⚠️: diagnosis is challenging, biomarkers are harder to interpret, & management is less straightforward

This @goKDIGO executive conclusions brought experts together to tackle these challenges

Here are the key takeaways👇
📄 #JACCHF: https://t.co/MHgmAxAeFX

@JACCJournals @lamcardio @BiykemB @JustinEzekowitz @jardine_meg @jozinetm @HeartDocSadiya @NishaKidneyDoc